Aurinia's 15min chart sees MACD Death Cross and KDJ Death Cross.

Aurinia's 15-minute chart exhibits a significant trend reversal, as evidenced by the occurrence of a MACD Death Cross and KDJ Death Cross on August 11, 2025 at 15:15. This development suggests that the stock price has the potential to continue declining, with a notable shift in momentum towards the downside. Consequently, there is a high probability that the stock price will experience further decreases.

Aurinia Pharmaceuticals Inc. (AUPH) experienced a significant trend reversal on August 11, 2025, at 15:15, as indicated by the occurrence of both a MACD Death Cross and a KDJ Death Cross on its 15-minute chart. This development suggests a potential continuation of the downward trajectory of the stock price, with a notable shift in momentum towards the downside. Consequently, there is a high probability that the stock price will experience further decreases.

The MACD Death Cross occurs when the MACD line crosses below the signal line, signaling a potential reversal in the stock's trend. The KDJ Death Cross, another technical indicator, reinforces this bearish signal by indicating a significant decline in the stock's momentum. Both indicators suggest that sellers are currently in control of the market, and the bearish momentum is likely to persist.

Aurinia Pharmaceuticals has shown remarkable momentum, delivering a 113% return over the past year. However, recent insider trading news indicates that Director Kevin Tang purchased 1,300,000 shares of Aurinia Pharmaceuticals Inc. between August 1 and August 5, 2025. The purchases were made at prices ranging from $10.12 to $11.68, for a total value of $13,590,000. This significant insider buying suggests a positive outlook from management despite the recent technical indicators.

The stock has been trading near its 52-week high of $11.48, and the latest analyst rating from RBC Capital on August 1, 2025, maintains an outperform rating with a price target of $9.00. However, the stock has recently crossed above the average analyst 12-month target price of $11.00, suggesting that investors should closely monitor the stock for potential valuation adjustments.

Investors should monitor Aurinia Pharmaceuticals closely for any signs of a potential reversal. The MACD Death Cross and KDJ Death Cross are strong indicators of a potential downtrend, and traders should be prepared for further declines in the stock's value.

References:
[1] https://www.ainvest.com/news/arena-group-15min-chart-triggered-macd-death-cross-kdj-death-cross-2508/
[2] https://www.investing.com/news/insider-trading-news/aurinia-pharma-director-tang-buys-1359m-in-shares-93CH-4171562
[3] https://www.benzinga.com/quote/AUPH/analyst-ratings
[4] https://www.nasdaq.com/articles/aurinia-pharmaceuticals-reaches-analyst-target-price
[5] https://www.barchart.com/stocks/quotes/AUPH/opinion/50-100-Day-MA-Crossover/strategy-charts